<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-120537</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">OnabotulinumtoxinA in chronic migraine: from the theory of clinical trials to clinical practice</dc:title>
<dc:description xml:lang="en">The introduction of OnabotulinumtoxinA (OnabotA) in the treatment of chronic migraine has brought with it  a significant change in the management of these patients. Its novel mechanism of action, the fact that it is administered  as an injection and the need to repeat treatment and control regimens all suggest the need to modify the therapeutic  strategy applied in this clinical situation. This article briefly reviews the main clinical evidence on the effectiveness of  OnabotA in chronic migraine based on the clinical trials conducted to date. At the same time it also performs a critical  analysis of the application of OnabotA in daily clinical practice. It includes the findings of a survey carried out on Spanish  neurologists about their experience in the application of OnabotA in patients with chronic migraine in order to determine   the real situation in our milieu. The main conclusions include the need to use suitable doses of OnabotA, together with  appropriate injection points, the non-exclusion of patients with very frequent crises, concomitant preventive treatment  or medication abuse, waiting up to 15 days in order to be able to observe the clinical effectiveness and not considering  OnabotA as ineffective until after having performed 2-3 infiltration regimens (AU)</dc:description>
<dc:creator>Leira, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">OnabotulinumtoxinA en la migraña crónica: de la teoría de los ensayos clínicos a la práctica clínica (AU)</dc:description>
<dc:source>Rev Neurol;58(supl.2): s3-s11, mar. 2014. tab, graf</dc:source>
<dc:identifier>ibc-120537</dc:identifier>
<dc:title xml:lang="es">OnabotulinumtoxinA en la migraña crónica: de la teoría de los ensayos clínicos a la práctica clínica</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d34281^s22080</dc:subject>
<dc:subject>^d28563^s22057</dc:subject>
<dc:subject>^d1930^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d3965</dc:subject>
<dc:subject>^d9068^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>201403</dc:date>
</metadata>
</record>
</ibecs-document>
